FDA Clinical Overview Presentation About Sublocade For The October 31, 2017, Joint Meeting Of The FDA Psychopharmacologic Drugs Advisory Committee & The Drug Safety & Risk Management Advisory Committee

On October 31, 2017, a clinical review subcommittee to advisory committees for the U.S. Food and Drug Administration (FDA) presented findings about a buprenorphine-atrigel one-month depot injection. The drug is intended for the treatment of moderate to severe opioid use disorder in adults who have started opioid treatment with a transmucosal buprenorphine-containing product . . .